AMLXAmylyx Pharmaceuticals, Inc.

$27.20+79% 1Y

$27.20

$11.3852 weeks$39.67

AMLX in its own filings

Nothing in AMLX's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.

Events found in the filings · across 438 filings · the record starts in 2021

Hard flags: none
Hard flags
Most recent filing: Sep 8, 2026
Most recent filing · Form 8-K
Record starts: May 28, 2021
Record starts · the earliest filing Ryufin holds for this name

Details›

Next results filingsame week as a year ago: expected around Nov 5, 2026
SEC comment-letter activity14 occurrences: 2025-03-24

SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.

What the company said

The company's own words from its current reports to the SEC, newest first

Sep 8, 2026On September 8, 2026, Amylyx Pharmaceuticals, Inc. (the “Company”) entered into a Manufacturing and Supply Agreement (the “Bachem Manufacturing Agreement”) with Bachem Americas, Inc. (“Bachem”) and on September 1, 2026, the Company entered into a term sheet (the “Polypeptide Term Sheet”) with Polypeptide Group AG …Material agreement entered · Form 8-K
Aug 20, 2026On August 19, 2026, Amylyx Pharmaceuticals, Inc. (“Amylyx” or the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, Morgan Stanley & Co. LLC, Guggenheim Securities, LLC, and LifeSci Capital LLC, as representatives of the several underwriters named therein (the …Material agreement entered · Form 8-K
Aug 18, 2026On August 18, 2026, Amylyx Pharmaceuticals, Inc. (the “Company”) hosted a conference call with investors and analysts to discuss positive topline results from the LUCIDITY Phase 3 clinical trial evaluating the efficacy and safety of avexitide in participants with post-bariatric hypoglycemia following Roux-en-Y gastric …Other event · Form 8-K
Aug 18, 2026On August 18, 2026, the Company announced positive topline results from LUCIDITY, a 78-participant, multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the efficacy and safety of avexitide, an investigational, first-in-class glucagon-like peptide-1 (“GLP-1”) receptor antagonist …Regulation FD disclosure · Form 8-K
Aug 6, 2026Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Results.Earnings release · press release
May 7, 2026Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results.Earnings release · press release
Jan 8, 2026On January 8, 2026, Amylyx Pharmaceuticals, Inc. (the “Company”) announced the selection of AMX0318, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist, as a development candidate for post-bariatric hypoglycemia and other rare diseases.Regulation FD disclosure · Form 8-K
Nov 6, 2025Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results.Earnings release · press release